This company has been marked as potentially delisted and may not be actively trading. Travere Therapeutics (RTRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock RTRX vs. MOR, GMTX, CALT, ZYME, MBX, SBTX, AVTE, BIOA, NLTX, and CYBNShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), MBX Biosciences (MBX), Silverback Therapeutics (SBTX), Aerovate Therapeutics (AVTE), BioAge Labs (BIOA), Neoleukin Therapeutics (NLTX), and Cybin (CYBN). Travere Therapeutics vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks MBX Biosciences Silverback Therapeutics Aerovate Therapeutics BioAge Labs Neoleukin Therapeutics Cybin MorphoSys (NASDAQ:MOR) and Travere Therapeutics (NASDAQ:RTRX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability. Does the media refer more to MOR or RTRX? In the previous week, Travere Therapeutics had 1 more articles in the media than MorphoSys. MarketBeat recorded 1 mentions for Travere Therapeutics and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 equaled Travere Therapeutics'average media sentiment score. Company Overall Sentiment MorphoSys Neutral Travere Therapeutics Neutral Which has more volatility & risk, MOR or RTRX? MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Do institutionals and insiders believe in MOR or RTRX? 18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 4.6% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is MOR or RTRX more profitable? Travere Therapeutics has a net margin of -49.13% compared to MorphoSys' net margin of -226.79%. Travere Therapeutics' return on equity of -36.38% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Travere Therapeutics -49.13%-36.38%-14.90% Which has higher valuation and earnings, MOR or RTRX? Travere Therapeutics has lower revenue, but higher earnings than MorphoSys. Travere Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45Travere Therapeutics$175.34M7.28-$146.43M-$3.46-7.23 SummaryTravere Therapeutics beats MorphoSys on 7 of the 12 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTRX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.28B$934.71M$5.86B$10.15BDividend YieldN/A4.84%5.68%4.59%P/E Ratio-11.851.1074.5225.93Price / Sales7.2826.70540.10123.77Price / CashN/A19.5637.5660.44Price / Book4.856.6912.166.29Net Income-$146.43M-$4.50M$3.28B$270.77M Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTRXTravere TherapeuticsN/A$25.00-8.5%N/A+112.7%$1.28B$175.34M-11.85221News CoverageHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$59.650.0%N/A+21.0%$2.58BN/A-59.6530CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180News CoverageZYMEZymeworks2.378 of 5 stars$14.01-5.4%$21.43+53.0%+34.9%$1.05B$122.87M-9.34460Positive NewsMBXMBX Biosciences2.8039 of 5 stars$14.57-3.4%$37.63+158.2%N/A$489.47MN/A-3.2136Positive NewsSBTXSilverback TherapeuticsN/A$11.62-9.6%N/A-8.8%$418.99MN/A-4.8083News CoverageHigh Trading VolumeAVTEAerovate TherapeuticsN/A$7.90-2.2%N/A-88.7%$228.98MN/A-2.6420Positive NewsHigh Trading VolumeBIOABioAge Labs0.1972 of 5 stars$4.65-5.7%N/AN/A$176.74MN/A0.00N/APositive NewsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$18.48-1.9%N/A-52.7%$173.68MN/A-5.9490CYBNCybin2.668 of 5 stars$6.24-16.6%$85.00+1,262.2%N/A$147.20MN/A-1.4250Gap DownHigh Trading Volume Related Companies and Tools Related Companies MorphoSys Alternatives Gemini Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Zymeworks Alternatives MBX Biosciences Alternatives Silverback Therapeutics Alternatives Aerovate Therapeutics Alternatives BioAge Labs Alternatives Neoleukin Therapeutics Alternatives Cybin Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTRX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
